Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes

Goldstein, Barry J., Feinglos, Mark N., Lunceford, Jared K., Johnson, Jeremy, Williams-Herman, Debora E., for the Sitagliptin 036 Study Group·2007·Diabetes Care
DOI 10.2337/dc07-0627

Cited by (510)

Items 201–300 of 510

  1. Evaluating Second-Line Treatment Options for Type 2 Diabetes: Focus on Secondary Effects of GLP-1 Agonists and DPP-4 Inhibitors
    Cassie L. Boland, Michelle DeGeeter, Donald S. Nuzum, Maria Tzefos · 2013 · Annals of Pharmacotherapy
  2. The 5-HT6 Receptor as a Target for Developing Novel Antiobesity Drugs
    David J. Heal, Jane Gosden, Sharon L. Smith · 2011 · International review of neurobiology
  3. Antidiabetic Oral Treatment in Older People
    Angela Marie Abbatecola, Giuseppe Paolisso, Andrea Corsonello, Silvia Bustacchini, Fabrizia Lattanzio · 2009 · Drugs & Aging
  4. Non‐glycaemic effects mediated via GLP‐1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide
    Tina Vilsbøll, Alan J. Garber · 2012 · Diabetes Obesity and Metabolism
  5. Incretin-based therapy in combination with basal insulin: A promising tactic for the treatment of type 2 diabetes
    Jiten P Vora, Stephen Charles Bain, Taner Damcı, Grzegorz Jan Dzida, Priscilla A. Hollander, Luigi Meneghini, S. Ross · 2012 · Diabetes & Metabolism
  6. Incretin‐based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials
    Haining Wang, Ye Liu, Qing Tian, Jin Yang, Ran Lu, Siyan Zhan, Jari K. Haukka, Tianpei Hong · 2017 · Diabetes Obesity and Metabolism
  7. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    Swati Srivastava, G N Saxena, Prakash Keshwani, Ritesh Gupta · 2012 · PubMed
  8. A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment
    Steve Bain, Vinay S. Eligar · 2013 · Drug Design Development and Therapy
  9. Drug evaluation: Vildagliptin-metformin single-tablet combination
    Abd A. Tahrani, Milan K. Piya, Anthony H Barnett · 2009 · Advances in Therapy
  10. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
    David M. Nathan, John B. Buse, Mayer B. Davidson, Ele Ferrannini, Rury R. Holman, Robert Sherwin, Bernard Zinman · 2009 · Clinical Diabetes
  11. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double‐blind randomized controlled trial ( INICOM study)
    Soo Kyung Lim, Kyung Ah Han, JaeMyung Yu, Parinya Chamnan, Eun Sook Kim, Kun‐Ho Yoon, Sam Hyun Kwon, Min Kyong Moon, Kwan Woo Lee, Dong‐Jun Kim et al. · 2016 · Diabetes Obesity and Metabolism
  12. Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study
    Robert R. Henry, Julio Rosenstock, Douglas Scott Denham, Prakash Prabhakar, Lise Kjems, Michelle A. Baron · 2018 · Diabetes Care
  13. Bioequivalence of Sitagliptin/Metformin Fixed-Dose Combination Tablets and Concomitant Administration of Sitagliptin and Metformin in Healthy Adult Subjects
    Elizabeth M. Migoya, Jutta Miller, Maria Gutierrez, Wei Zheng, Amy O. Johnson‐Levonas, Qi Liu, Catherine Zhou Matthews, John A. Wagner, Keith M Gottesdiener · 2010 · Clinical Drug Investigation
  14. Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia
    James Taylor, Morgan Anderson, Jason Powell, Kendall M. Campbell · 2014 · Diabetes Metabolic Syndrome and Obesity
  15. Inhibition of proteases as a novel therapeutic strategy in the treatment of metabolic, inflammatory and functional diseases of the gastrointestinal tract
    Maciej Sałaga, Marta Sobczak, Jakub Fichna · 2013 · Drug Discovery Today
  16. Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight
    William I. Sivitz, Lawrence S. Phillips, Deborah J. Wexler, Stephen P. Fortmann, ANNE W. CAMP, Margaret Tiktin, Magalys Perez, Jacqueline Craig, Priscilla A. Hollander, Andrea Cherrington et al. · 2020 · Diabetes Care
  17. Can Newer Therapies Delay the Progression of Type 2 Diabetes Mellitus?
    Edward S. Horton · 2008 · Endocrine Practice
  18. In support of an early polypharmacy approach to the treatment of type 2 diabetes
    Eugene E. Wright, Anthony H. Stonehouse, Robert M Cuddihy · 2010 · Diabetes Obesity and Metabolism
  19. Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis
    Manuj Sharma, Nicholas Beckley‐Hoelscher, Irwin Nazareth, Irene Petersen · 2017 · BMJ Open
  20. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies
    Alfred Penfornis, Sophie Borot, D. Raccah · 2008 · Diabetes & Metabolism
  21. Current Strategies for Evaluating, Monitoring, and Treating Type 2 Diabetes Mellitus
    Jeff Unger · 2008 · The American Journal of Medicine
  22. Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study
    Eu Jeong Ku, Kyong Yeon Jung, Yoon Ji Kim, Kyoung Min Kim, Jae Hoon Moon, Sung Hee Choi, Young Min Cho, Kyong Soo Park, Hak Chul Jang, Soo Kyung Lim et al. · 2015 · PLoS ONE
  23. Sitagliptin/Metformin Fixed-Dose Combination
    Claudine M. Chwieduk · 2011 · Drugs
  24. Teneligliptin: Heralding Change in Type 2 Diabetes
    Manish Nilkanth Maladkar, Srividya Sankar, Kushal Kamat · 2016 · Journal of Diabetes Mellitus
  25. Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?
    I. W. Campbell · 2010 · International Journal of Clinical Practice
  26. Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta‐analysis
    Katherine R. Gerrald, Erin Van Scoyoc, Roberta Wines, Thomas M. Runge, Daniel E Jonas · 2011 · Diabetes Obesity and Metabolism
  27. The Place of GLP-1–Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists
    Dara L. Eckerle Mize, Marzieh Salehi · 2013 · Current Diabetes Reports
  28. Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in J apanese patients with type 2 diabetes over 52 weeks
    Takashi Kadowaki, Naoko Tajima, Masato Odawara, Mikio Nishii, Tadaaki Taniguchi, Juan Camilo Arjona Ferreira · 2012 · Journal of Diabetes Investigation
  29. Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes
    Matilda Florentin, Evangelos N. Liberopoulos, Dimitri P. Mikhailidis, Moses Elisaf · 2008 · Expert Opinion on Pharmacotherapy
  30. Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue
    Kjetil Retterstøl · 2009 · Expert Opinion on Investigational Drugs
  31. Short‐term intensive insulin therapy could be the preferred option for new onset T ype 2 diabetes mellitus patients with HbA1c > 9%
    Jianping Weng · 2017 · Journal of Diabetes
  32. Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials
    Han Chen, Xiaoying Zhou, Tao Chen, Bingtuan Liu, Wujuan Jin, Huiyuan Gu, Tianyuan Hong, Guoxin Zhang · 2016 · Diabetes Therapy
  33. Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double‐blind, active‐controlled, parallel group, multinational clinical trial
    S. Ross, Augusto Enrique Caballero, Stefano Del Prato, Baptist Gallwitz, Diane J. Lewis-D’Agostino, Zelie Bailes, Sandra Thiemann, Sakshi Patel, Hans Juergen Woerle, Maximilian von Eynatten · 2014 · Diabetes Obesity and Metabolism
  34. Effects of 6-Month Sitagliptin Treatment on Glucose and Lipid Metabolism, Blood Pressure, Body Weight and Renal Function in Type 2 Diabetic Patients: A Chart-Based Analysis
    Hidekatsu Yanai · 2012 · Journal of Clinical Medicine Research
  35. Managing Type 2 Diabetes: Balancing HbA1cand Body Weight
    Annie A. Mavian, Stephan Miller, Robert R. Henry · 2010 · Postgraduate Medicine
  36. Primary prevention of cardiovascular disease in older adults in China
    Jian Yong, Dong Lin, Xuerui Tan · 2017 · World Journal of Clinical Cases
  37. Elevated Hepatic Enzymes Potentially Associated with Sitagliptin
    Ben Gross, L. Brian Cross, Joni C. Foard, Yelena Wood · 2010 · Annals of Pharmacotherapy
  38. Incretin-based therapies: new treatments for type 2 diabetes in the new millennium
    Michael Horowitz · 2009 · Therapeutics and Clinical Risk Management
  39. Exploring Treatment Strategies for Type 2 Diabetes
    Zachary T. Bloomgarden · 2007 · Diabetes Care
  40. Glycemic Effectiveness of Metformin-Based Dual-Combination Therapies with Sulphonylurea, Pioglitazone, or DPP4-Inhibitor in Drug-Naïve Korean Type 2 Diabetic Patients
    Young Ki Lee, Sun Ok Song, Kwang Joon Kim, Yongin Cho, YounJeong Choi, Yujung Yun, Byung‐Wan Lee, Eun Seok Kang, Bong Soo, Hyun Chul Lee · 2013 · Diabetes & Metabolism Journal
  41. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy
    Regin Elsa George, Siby Joseph · 2013 · Saudi Pharmaceutical Journal
  42. Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis
    Qiang Du, Bo Wu, Yanjun Wang, Sheng Yang, Yueyang Zhao, Yuanyuan Liang · 2013 · Current Medical Research and Opinion
  43. Effect of Sitagliptin as Add-on Therapy in Elderly Type 2 Diabetes Patients With Inadequate Glycemic Control in Taiwan
    Ming-Nan Chien, Chun‐Chuan Lee, Wei-Che Chen, Sung-Chen Liu, Ching-Hsiang Leung, Chao‐Hung Wang · 2011 · International journal of gerontology
  44. Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone
    R. Chapell, A. Lawrence Gould, Charles M. Alexander · 2009 · Diabetes Obesity and Metabolism
  45. Incretin-based therapies in type 2 diabetes: A review of clinical results
    Emanuele Bosi, Pietro Lucotti, Emanuela Setola, Lucilla Domenica Monti, Pier Marco Piatti · 2008 · Diabetes Research and Clinical Practice
  46. Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
    Tae Jung Oh, Jae Myung Yu, Kyung Wan Min, Hyun Shik Son, Moon Kyu Lee, Kun‐Ho Yoon, Young Duk Song, Joong Yeol Park, In‐Kyung Jeong, Bong Soo et al. · 2018 · Diabetes & Metabolism Journal
  47. Targeting skeletal muscle mitochondrial health in obesity
    Pileggi, Chantal A., Hooks, Breana G., McPherson, Ruth, Dent, Robert R.M., Harper, Mary-Ellen · 2022 · Clinical Science
  48. Synthetic (+)‐antroquinonol exhibits dual actions against insulin resistance by triggering AMP kinase and inhibiting dipeptidyl peptidase IV activities
    Chia‐Tien Hsu, Rohidas S. Sulake, P‐K Huang, H‐Y Shih, H‐W Sie, Y‐K Lai, C Chen, Ching‐Feng Weng · 2014 · British Journal of Pharmacology
  49. Chronic Continuous Exenatide Infusion Does Not Cause Pancreatic Inflammation and Ductal Hyperplasia in Non-Human Primates
    Teresa Vanessa Fiorentino, Michael A. Owston, GREGORY A. ABRAHAMIAN, Stefano La Rosa, Alessandro Marando, Carla Perego, E.S. Di Cairano, Giovanna Finzi, Carlo Capella, Fausto Sessa et al. · 2014 · American Journal Of Pathology
  50. Metformin: A Review of Its Use in the Treatment of Type 2 Diabetes
    Νικόλαος Παπάνας, Efstratios S. Maltezos · 2009 · Clinical Medicine Therapeutics
  51. Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy
    Jennifer Green · 2010 · Drug Healthcare and Patient Safety
  52. Risk of Skin Cancer Associated with Metformin Use: A Meta-Analysis of Randomized Controlled Trials and Observational Studies
    Michael S. Chang, Rebecca Ivy Hartman, Junchao Xue, Edward L. Giovannucci, Hongmei Nan, Keming Yang · 2020 · Cancer Prevention Research
  53. Diabetes: glycaemic control in type 2 (drug treatments).
    Kees J. Gorter, Floris A Van de Laar, P. G. H. Janssen, Sebastiaan T. Houweling, Guy E.H.M. Rutten · 2012 · Europe PMC (PubMed Central)
  54. Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy
    Jeffrey Wayne Stephens, Rosie Anderson, Jenny Hayes · 2016 · Drug Design Development and Therapy
  55. Weight Management in Overweight and Obese Patients with Type 2 Diabetes Mellitus
    Ioannis Kyrou, Sudhesh Kumar · 2010 · The British Journal of Diabetes
  56. Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes
    Sunder Raj D. Mudaliar · 2013 · International Journal of Clinical Practice
  57. Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and β-Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis
    Jaehyun Bae, Gyuri Kim, Yong‐ho Lee, Byung‐Wan Lee, Eun Seok Kang, Bong Soo · 2018 · Diabetes Therapy
  58. Safety and Efficacy of Sitagliptin-Metformin in Fixed Combination for the Treatment of Type 2 Diabetes Mellitus
    Chitrabhanu Ballav, Stephen C. L. Gough · 2013 · Clinical Medicine Insights Endocrinology and Diabetes
  59. Therapeutic Potential of Various Intermittent Fasting Regimens in Alleviating Type 2 Diabetes Mellitus and Prediabetes: A Narrative Review
    Sthembiso Msane, Andile Khathi, Aubrey Mbulelo Sosibo · 2024 · Nutrients
  60. International Diabetes Center Treatment of Type 2 Diabetes Glucose Algorithm
    Gregg Simonson, Robert M Cuddihy, Diane Reader, Richard M. Bergenstal · 2011 · Diabetes Management
  61. Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis
    Shubing Jia, Zhiying Wang, Ruobing Han, Zinv Zhang, Yuping Li, Xiaotong Qin, Mingyi Zhao, Rongwu Xiang, Jingyu Yang · 2020 · Acta Diabetologica
  62. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus
    Robert M. Guthrie · 2015 · Postgraduate Medicine
  63. Sitagliptin in the treatment of type 2 diabetes: a meta‐analysis
    Mei Zhan, Ting Xu, Fengbo Wu, Tang Yao · 2012 · Journal of Evidence-Based Medicine
  64. Impact of Three Oral Antidiabetic Drugs on Markers of β-Cell Function in Patients with Type 2 Diabetes: A Meta-Analysis
    Jin Lu, Jiajie Zang, Hui‐Hua Li · 2013 · PLoS ONE
  65. Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
    Stanley S. Schwartz · 2010 · Diabetes Metabolic Syndrome and Obesity
  66. A randomized clinical trial to evaluate the single-dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes
    Iain P. Fraser, Naomi D Neufeld, Larry A. Fox, Mark S. Kipnes, Tracie L. Miller, Philip Scott Zeitler, Henry Rodriguez, Jocelyn Gilmartin, Sang Hyuck Lee, Jaclyn K. Patterson et al. · 2018 · Pediatric Diabetes
  67. Janumet™: a combination product suitable for use in patients with Type 2 diabetes
    Jonathan K. Reynolds, Joshua J. Neumiller, R. Keith Campbell · 2008 · Expert Opinion on Investigational Drugs
  68. Clinical Characteristics of the Responders to Dipeptidyl Peptidase-4 Inhibitors in Korean Subjects with Type 2 Diabetes
    Tae Jung Oh, Hye Seung Jung, Jae Hyun Bae, Yeong Gi Kim, Kyeong Seon Park, Young Min Cho, Kyong Soo Park, Seong Yeon Kim · 2013 · Journal of Korean Medical Science
  69. Effect of Sitagliptin and Metformin on Prediabetes Progression to Type 2 Diabetes - A Randomized, Double-Blind, Double-Arm, Multicenter Clinical Trial: Protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) Study
    Poobalan Naidoo, Jeffrey Wing, Virendra Rambiritch · 2016 · JMIR Research Protocols
  70. Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials
    Khosro Keshavarz, Farhad Hosseinzadeh Lotfı, Ehsan Sanati, Mahmood Salesi, Amir Hashemi-Meshkini, Mojtaba Jafari, Mohammad M. Mojahedian, Behzad Najafi, Shekoufeh Nikfar · 2017 · DARU Journal of Pharmaceutical Sciences
  71. Enhanced glycemic control with combination therapy for type 2 diabetes in primary care
    Louis Kuritzky, George P. N. Samraj · 2011 · Diabetes Therapy
  72. Efficacy and Safety of Sitagliptin in the Treatment of Type 2 Diabetes
    Roger Gadsby · 2009 · Clinical Medicine Therapeutics
  73. Weight Management in Type 2 Diabetes Mellitus
    Amulya T. Siram, Robert T. Yanagisawa, Maria Skamagas · 2010 · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine
  74. Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis
    Li-qiong Hou, Tie-yun Zhao, YUNHUI LIU, Yiyi Zhang · 2015 · Experimental and Therapeutic Medicine
  75. Sitagliptin/Metformin (janumet) as combination therapy in the treatment of type-2 diabetes mellitus.
    Erin St. Onge, Shannon A. Miller, Elizabeth A. Clements · 2012 · PubMed Central
  76. Effects of saxagliptin on glucose homeostasis and body composition of obese patients with newly diagnosed pre-diabetes
    Zixuan Wang, Dengcheng Xu, Lanhui Huang, Tiantian Zhang, Junqiao Wang, Qing Chen, Lei Kong, Xinli Zhou · 2017 · Diabetes Research and Clinical Practice
  77. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone
    Clifford J. Bailey, Brian D. Green, Peter R. Flatt · 2010 · Expert Opinion on Investigational Drugs
  78. Glucagon‐like peptide‐1‐based therapies: new developments and emerging data
    Alan J. Garber · 2008 · Diabetes Obesity and Metabolism
  79. Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
    Shannon A. Miller · 2009 · Diabetes Metabolic Syndrome and Obesity
  80. DPP-4 Inhibitor-Induced Rheumatoid Arthritis Among Diabetics: A Nested Case–Control Study
    Niranjan J. Kathe, Anuj Shah, Qayyim Said, Jacob T. Painter · 2017 · Diabetes Therapy
  81. DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
    Erna Kristin · 2016 · Journal of the Medical Sciences (Berkala Ilmu Kedokteran)
  82. Double‐blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT‐M study
    Juan P. Frías, Zachary Zimmer, Raymond L. H. Lam, G. Suárez Amorín, Catherine Ntabadde, Carol Iredale, Edward A. O’Neill, Samuel S. Engel, Keith D. Kaufman, Hideo Makimura et al. · 2019 · Diabetes Obesity and Metabolism
  83. Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes
    Rosemarie Lajara · 2012 · Expert Opinion on Pharmacotherapy
  84. Pharmacotherapy of hyperglycemia
    Kristen M. Kulasa, Robert R. Henry · 2009 · Expert Opinion on Pharmacotherapy
  85. The dipeptidyl‐peptidase‐4 (DPP‐4) inhibitors: a new class of oral therapy for patients with type 2 diabetes mellitus
    MA Elrishi, Kamlesh Khunti, Janet Jarvis, MJ Davies · 2007 · Practical Diabetes
  86. Incorporating Incretin-Based Therapies into Clinical Practice for Patients with Type 2 Diabetes
    Joseph M. Tibaldi · 2014 · Advances in Therapy
  87. Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes
    Bhavana Sosale, Aravind Sosale, Arpandev Bhattacharyya · 2016 · Diabetes Therapy
  88. Efficacy and safety of the G protein‐coupled receptor 119 agonist DS‐8500a in Japanese type 2 diabetes mellitus patients with inadequate glycemic control on sitagliptin: A phase 2 randomized placebo‐controlled study
    Yasuo Terauchi, Yuichiro Yamada, Hirotaka Watada, Yasuhiko Nakatsuka, Kazuhito Shiosakai, Takuo Washio, Takashi Taguchi · 2018 · Journal of Diabetes Investigation
  89. Comparative evaluation of incretin‐based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure†
    Michael Albrecht Nauck, Irfan Vardarli · 2010 · Journal of Diabetes Investigation
  90. Implications of incretin-based therapies on cardiovascular disease
    Melissa E. Rotz, Valerie S. Ganetsky, S. Sen, Tyan F. Thomas · 2014 · International Journal of Clinical Practice
  91. Efficacy and safety of sitagliptin/metformin fixed‐dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double‐blind study
    Sang Soo Kim, In Joo Kim, Kwang Jae Lee, Jeong Hyun Park, Young Il Kim, Young Sil Lee, Sung Chang Chung, Sang Jin Lee · 2016 · Journal of Diabetes
  92. Glycemic Improvement with a Fixed‐dose combination of DPP ‐4 inhibitor + metformin in patients with Type 2 diabetes ( GIFT study)
    HARPREET SINGH BAJAJ, Chenglin Ye, Esha Jain, Karri Venn, Eden Stein, Ronnie Aronson · 2017 · Diabetes Obesity and Metabolism
  93. Defining the Importance of Daily Glycemic Control and Implications for Type 2 Diabetes Management
    Bruce W. Bode · 2009 · Postgraduate Medicine
  94. Hormone-based therapies in the regulation of fuel metabolism and body weight
    Nicole C. Kesty, Jonathan David Roth, David G. Maggs · 2008 · Expert Opinion on Biological Therapy
  95. Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview
    Carolyn Robertson · 2011 · Diabetes Spectrum
  96. Type 2 Diabetes in Adults
    2011 · Wiley eBooks
  97. Long-term safety, tolerability, and efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes
    Masato Odawara, Takashi Kadowaki, Naoko Tajima, Mikio Nishii, Tadaaki Taniguchi, Juan Camilo Arjona Ferreira · 2011 · Diabetology International
  98. Assessment of AACE/ACE Recommendations for Initial Dual Antihyperglycemic Therapy Using the Fixed-Dose Combination of Sitagliptin and Metformin Versus Metformin
    Samuel S. Engel, Thomas L. Seck, Gregory T. Golm, Alan G. Meehan, Keith D. Kaufman, Barry J. Goldstein · 2013 · Endocrine Practice
  99. Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus
    Chu Lin, Xiaoling Cai, Wenjia Yang, Fang Lv, Lin Nie, Linong Ji · 2020 · BMC Medicine
  100. Initial Combination with Linagliptin and Metformin in Newly Diagnosed Type 2 Diabetes and Severe Hyperglycemia
    Thomas Haak · 2012 · Advances in Therapy